Hetero Labs to manufacture 100 million doses of Sputnik V vaccineIllustrative image – not actual.
Hyderabad-based Hetero Labs will be working with the Russian Direct Investment Fund (RDIF) to produce 100 million doses per year of the Sputnik V vaccine.

The parties intend to start production of Sputnik V in the beginning of 2021. The fund was planning to supply one billion doses of Sputnik V across the globe in 2021 and had forged partnerships in India, China, Brazil, Korea, Hungary and some other locations.

Another Hyderabad-based player Dr Reddy's Laboratories (DRL) is RDIF's partner in India for conducting clinical trials and distribution of the vaccine. It had indicated this month that the process of technology transfer had begun at its partner site (for manufacturing) in India. The first batch of Sputnik V vaccines has also arrived for clinical trial purposes.

The Sputnik V vaccine has been priced at USD 10 per dose. It is a two-dose course.

Further, to make the logistics easy, a variant is being developed that will remain stable at two-eight degree Celsius. This will be a lyophilised version.

← All latest storiesBack to top →